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of glycated proteins leads to cumulative chemical modifications
of tissue proteins throughout the body. These chemical
changes, collectively termed the Maillard reaction, are considered to cause a gradual deterioration in the structure and
function of tissue proteins and to contribute to the pathophysiology of normal aging (1–3). Further, the Maillard reaction is
accelerated during hyperglycemia in diabetes, yielding advanced glycation end products (AGEs)1 thought to be involved
in the pathogenesis of diabetic complications (4 – 6). Among
Maillard reaction products identified thus far in tissue proteins, concentrations of pentosidine (3, 7) and N e-(carboxymethyl)lysine (CML) (7) are known to increase in human skin
collagen with age, and age-adjusted concentrations of both are
increased in skin collagen in diabetes (7). Moreover, there is a
strong relationship between levels of these products in collagen
and the status of diabetic complications (8 –10). Both CML and
pentosidine require oxidative conditions for their formation,
hence their description as glycoxidation products (11). Recently
we showed that CML can also be formed during the reaction of
autoxidizing polyunsaturated fatty acids (PUFA) with proteins
(12), so that its precise biochemical origin is uncertain. The
formation of CML during both glycoxidation and lipoxidation
reactions emphasizes that Maillard chemistry is a general reflection of carbonyl amine reactions, whether the carbonyl compounds are derived from carbohydrates or lipids.
Several recent reports indicate that, like proteins, aminophospholipids are also targets of Maillard reactions.
Pamplona et al. (13) first showed evidence for the presence of
glycated phospholipids in rat liver and found their levels increased in animals with streptozotocin-induced diabetes.
Ravandi et al. (14) further documented the existence of glycated aminophospholipids in human red blood cells and
plasma, although their analytical technique did not distinguish
between Schiff base and Amadori compounds, both of which are
formed during the initial stage of the reaction of glucose with
amino groups (1). Bucala et al. (15, 16) show in vitro that
glycation of phosphatidylethanolamine (PE) but not phosphatidylcholine resulted in the formation of immunologically detectable AGEs in PE. In addition, using an ELISA assay, these
authors concluded that the majority of AGEs present in low
density lipoprotein isolated from normal and diabetic subjects
1
The abbreviations used are: AGE, advanced glycation end product;
AGE-RbSA, AGE rabbit serum albumin; CM, carboxymethyl; CML,
N e-(carboxymethyl)lysine; CME, carboxymethylethanolamine; PUFA,
polyunsaturated fatty acids; PE, phosphatidylethanolamine; DO-PE,
dioleoyl-PE; LP-PE, linoleoylpalmitoyl-PE; ELISA, enzyme-linked immunosorbent assay; GC/MS, gas chromatography-mass spectrometry;
SIM-GC/MS, selected ion monitoring-GC/MS; PSR-1, anti-AGE protein
antiserum; FL, fructose-lysine; TFAME, N,O-trifluoroacetyl methyl esters; BSA, bovine serum albumin.
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N e-(Carboxymethyl)lysine (CML) is a stable chemical
modification of proteins formed from both carbohydrates and lipids during autoxidation reactions. We hypothesized that carboxymethyl lipids such as (carboxymethyl)phosphatidylethanolamine (carboxymethylPE) would also be formed in these reactions, and we
therefore developed a gas chromatography-mass spectrometry assay for quantification of carboxymethylethanolamine (CME) following hydrolysis of phospholipids.
In vitro, CME was formed during glycation of dioleoyl-PE under air and from linoleoylpalmitoyl-PE, but
not from dioleoyl-PE, in the absence of glucose. In vivo,
CME was detected in lipid extracts of red blood cell
membranes, ;0.14 mmol of CME/mol of ethanolamine,
from control and diabetic subjects, (n 5 22, p > 0.5).
Levels of CML in erythrocyte membrane proteins were
;0.2 mmol/mol of lysine for both control and diabetic
subjects (p > 0.5). For this group of diabetic subjects
there was no indication of increased oxidative modification of either lipid or protein components of red cell
membranes. CME was also detected in fasting urine at
2–3 nmol/mg of creatinine in control and diabetic subjects (p 5 0.085). CME inhibited detection of advanced
glycation end product (AGE)-modified protein in a competitive enzyme-linked immunosorbent assay using an
anti-AGE antibody previously shown to recognize CML,
suggesting that carboxymethyl-PE may be a component
of AGE lipids detected in AGE low density lipoprotein.
Measurement of levels of CME in blood, tissues, and
urine should be useful for assessing oxidative damage to
membrane lipids during aging and in disease.
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were localized in the lipid phase (17). We recently identified
CML as a major AGE antigen, and based on similarities in the
structure of CML and CM-phospholipids such as CM-PE (Fig.
1), we proposed that AGE lipids may in fact, be immunologically cross-reactive carboxymethyl derivatives of aminophospholipids (18). Bucala et al. (15) also suggested that phospholipid glycation enhances lipid peroxidation. The interplay
between glycation, glycoxidation, and lipid peroxidation may
indeed be even more complex, since reaction of lipid decomposition products generated during peroxidative reactions with
free amino groups of both proteins and aminophospholipids
could lead to the formation of adducts chemically indistinguishable from carbohydrate-derived AGEs.
In the present study, we have developed a selected ion monitoring gas chromatography-mass spectrometry (SIM-GC/MS)
assay for carboxymethylethanolamine (CME), the hydrolysis
product of CM-PE, and present evidence for the presence of
CME in human red cell membrane lipids and as a metabolite in
urine. We also compare levels of CM protein and CM lipid in
the red cell membrane and present their comparative levels in
red blood cell ghosts in a group of control and diabetic individuals. Further, to gain insight into the nature of AGE lipids, we
show that free CME can compete with protein-bound CML for
recognition by an anti-AGE protein antiserum (PSR-1) previously shown to recognize CML as its primary epitope (18).
EXPERIMENTAL PROCEDURES

Materials—Glyoxylic acid and ethanolamine were purchased from
Aldrich, d4-ethanolamine was from Cambridge Isotope Laboratories
(Andover, MA), and NaBH4, NaBH3CN, sarcosine, Dowex 50, dioleoylphosphatidylethanolamine (DO-PE), and linoleoylpalmitoylphosphatidylethanolamine (LP-PE) were from Sigma.
Synthesis and Isolation of CME and d4-CME—Ethanolamine (0.33
mmol) and glyoxylic acid (1.33 mmol) were dissolved in 3 ml of phosphate buffer, pH 7.4. The mixture was heated at 65 °C for 1 h to allow
Schiff base formation; solid NaBH3CN (0.33 mmol) was added, and the
incubation was continued for an additional 2 h. Excess NaBH3CN was
discharged by the addition of 1 ml of 6 N HCl, and the reaction mixture
was dried in vacuo. Removal of borate as its methyl ester (19) was
accompanied by the formation of a white precipitate of salts that was
removed by centrifugation. After drying the supernatant in vacuo, the
yellowish residue was dissolved in water, the pH was adjusted to 2.5
with formic acid, and the sample was applied to a 12-ml Dowex 50
cation exchange column equilibrated in dilute formic acid (pH 3). The
column was washed with ;20 ml of the same formic acid solution and
eluted with 0.5 N NH4OH. Fractions (7 ml) were collected, the pH was
measured, and the first 4 fractions after the pH became basic were
pooled and dried. The sample was redissolved in 1% trifluoroacetic acid
and applied to a 1-ml C-18 Sep-Pak column (Supelco Inc., Bellefonte,
PA) equilibrated in the same solvent to remove brown impurities that
were retained on the column. The column was washed with 2 volumes
of 1% trifluoroacetic acid, and the eluates were combined and dried. The
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FIG. 1. Structures of CML and CME in protein and lipid. Enlarged portions emphasize the common features of each structure. The
protein backbone is indicted by compressed wave lines and the diacylglyceride component of phospholipid is represented by relaxed wave
lines.

residue contained essentially pure CME, based on both amino acid and
GC/MS analyses (see below). d4-CME was prepared by the same procedure, using d4-ethanolamine. Quantification of CME and d4-CME
standards was performed by cation exchange chromatography with
postcolumn ninhydrin detection, using sarcosine as the primary
standard.
Study Population—Patients with both insulin-dependent and noninsulin-dependent diabetes mellitus and control subjects were studied at
the Medical University of South Carolina. The study was approved by
the Institutional Review Board, and informed consent was obtained
from all subjects. Control and diabetic groups were matched for age
(26.6 6 7.4 years, 26.7 6 8.8 years, respectively), race (Caucasian/
African American, 10/1), and gender (F/M, 6/5). Among diabetic subjects, the distribution of insulin-dependent to noninsulin-dependent
diabetes mellitus was 9/2, and the average duration of diabetes was
8.3 6 7.5 years. HbA1c values in control and diabetic blood were 5.7 6
0.6% and 10.7 6 2.7%, respectively (p , 0.0001). Patients were free of
the vascular complications of diabetes, except for one patient who had
both background retinopathy and microalbuminuria.
Isolation of Red Blood Cell Membrane Lipids and Proteins—Blood
was collected into EDTA-containing Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ), and all subsequent procedures were carried
out at 4 °C. After centrifugation to separate plasma from red cells, red
blood cell ghosts from ;8 ml of packed red cells were prepared by the
method of Dodge et al. (20). Ghosts in 1 ml of 0.005 M phosphate buffer,
pH 7.4, were supplemented with 1 mM diethylenetriaminepentaacetic
acid and 0.01% butylated hydroxytoluene and then dried in vacuo. The
membranes were extracted twice using chloroform/methanol (2:1); the
lipid extracts were pooled, dried in vacuo, reduced with 100 mM NaBH4
in methanol, and dried again. Ethanolamine and CME were measured
in acid hydrolysates of the lipid extracts as described below. The extracted protein residues were dried and then acid-hydrolyzed, and CML
and fructose-lysine (FL) were measured in the hydrolysates after derivatization as their N,O-trifluoroacetyl methyl esters (TFAME), all as
described previously (19).
Analyses of Urine Samples—Second-voided fasting urine samples
were obtained from all subjects and frozen at 270 °C until used. Aliquots containing ;100 mg of creatinine were mixed with 2 volumes of
0.2 M borate buffer, pH 9.2. NaBH4 was added to a final concentration
of 200 mM, and reduction was carried out overnight at room temperature. Excess borohydride was discharged by the addition of several
drops of concentrated HCl, and borate was removed (19). After drying,
deuterated internal standards were added, and samples were hydrolyzed in 6 N HCl for 24 h at 110 °C in screw cap test tubes that were
purged with N2. Hydrolysates were dried in vacuo and rehydrated in 1
ml of 1% trifluoroacetic acid, and brown impurities were removed using
a 1-ml C-18 column as described above. The TFAME derivatives of the
sample were prepared (19) and analyzed by SIM-GC/MS as described
below. Creatinine was measured using a commercial kit (Sigma).
Glycoxidation and Autoxidation of PE—Incubations of PE with and
without glucose were conducted in 0.2 M phosphate buffer, pH 7.4, for 2
weeks at 37 °C and were carried out under both oxidative and antioxidative conditions. For antioxidative conditions, samples in plain Vacutainer tubes were supplemented with 1 mM diethylenetriaminepentaacetic acid and 0.01% butylated hydroxytoluene, and the tubes were
evacuated and flushed 3 3 with nitrogen. For oxidative conditions,
diethylenetriaminepentaacetic acid and butylated hydroxytoluene were
omitted, and samples were opened every other day to allow entry of air.
Lipids were extracted into chloroform/methanol (2:1), dried, and reduced with 50 mM NaBH4 in 1 ml of methanol overnight at room
temperature. Reduced lipids were dried in vacuo and, following the
addition of deuterated internal standards, were hydrolyzed in 1 ml of
6N HCl for 24 h at 110 °C. After drying, the TFAME derivatives of the
hydrolysates were prepared (19), and ethanolamine and CME were
quantified by SIM-GC/MS as described below.
GC/MS Analyses—Analyses of TFAME derivatives of all samples
except urine were carried out on a Hewlett-Packard model 6890 gas
chromatograph equipped with a 30-m HP-5MS capillary column coupled to a Hewlett-Packard model 6890 mass selective detector (HewlettPackard, Palo Alto, CA). The injection port was maintained at 275 °C.
The temperature program was 60 °C to 115 °C at 2 °C/min, then ramp
to 300 °C at 100 °C/min, and hold for 5 min. Quantification was by
internal standardization using standard curves constructed from mixtures of deuterated and nondeuterated standards. SIM of 2 ions/analyte
was performed, and similar results were obtained using both ions. The
ions used were ethanolamine and d4-ethanolamine, m/z 5 140, 184 and
144, 188, respectively; CME and d4-CME, m/z 5 211, 266 and 214, 270,
respectively (Fig. 2). Analyses of urine samples, which contained
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FIG. 2. Full scan spectra and fragmentation patterns of ethanolamine and CME. TFAME derivatives of authentic ethanolamine and
synthetic CME are shown in A and B, respectively. The molecular ion of
the CME (m/z 5 325) was confirmed by chemical ionization mass
spectrometry (data not shown).
numerous interfering substances, were carried out on a Hewlett-Packard model 5890 gas chromatograph equipped with a 30-m RTX 5 (5%
phenyl) column (Restek Corp., Bellefonte, PA) coupled to a high resolution VG 70 SQ magnetic sector mass spectrometer (Fisons, Manchester, UK). The injection port was maintained at 250 °C. The temperature
program was 2 min at 80 °C, ramp at 5 °C/min to 220 °C, ramp at
10 °C/min to 300 °C, and hold for 10 min. The same ions as listed above
were monitored for measurement of ethanolamine and CME.
Immunochemical Assays—Competitive ELISA assays were performed by the method of Reddy et al. (18) with minor modifications.
Briefly, 96-well polystyrene plates coated with AGE rabbit serum albumin (AGE-RbSA) (20 ng/well) were incubated with mixtures of competing antigens and a 1:5000 dilution of rabbit antiserum PSR-1. Antibody
binding was detected using peroxidase-conjugated anti-rabbit IgG as
second antibody.
Statistical Analysis—All data are expressed as mean 6 S.D., and
significance was assessed by Mann-Whitney nonparametric analysis.
RESULTS

Characterization of CME Formation on PE by Lipoxidaton or
Glycoxidation—CME may be formed on PE by at least three
routes (Scheme 1), including glycation of PE and oxidative
cleavage of the Amadori adduct or from the reaction of glyoxal
formed by autoxidation of glucose or PUFA. CME was produced

during autoxidation of PL-PE in phosphate buffer (Fig. 3A,
Table I) but not under antioxidative conditions. These results
are consistent with the formation of glyoxal during PUFA autoxidation (12, 21, 22). CME was also formed in incubations of
DO-PE with glucose (Fig. 3B, Table I) but not from DO-PE
incubated in buffer only. Although the glucose levels in these
incubations are clearly nonphysiological, the reaction conditions were modeled on those of Bucala et al. (15) because of the
detection of AGE lipid in this system. CME was also produced,
but at lower yield (10 –15%), in antioxidative incubations of
DO-PE with glucose (Table I). This finding was consistent in
three separate experiments. Both oxidative and antioxidative
incubations of DO-PE in the presence of glucose developed a
brown color with time, indicating that even in the absence of
PUFA, aminophospholipids are active substrates for the Maillard reaction in aqueous systems. LP-PE developed a light
yellow color during 2 weeks of incubation under air.
The amounts of CME formed after 2 weeks of incubation of
various reaction mixtures are summarized in Table I. Whereas
the concentration of LP-PE was only 10% that of DO-PE, for
reasons of economy, the amount of CME formed under oxidative conditions in LP-PE was about half that of DO-PE incubated with glucose. Thus, autoxidation of PE containing unsaturated PUFA was an efficient source of CME. The CME
detected in samples prepared in vitro and from in vivo sources
(see below) was measured after reduction with NaBH4 so that
its formation as an artifact from either carbohydrate or lipid
adducts during acid hydrolysis is unlikely.
Quantification of CME, CML, and FL in Red Cell Ghosts—As
shown in Fig. 4, CME was readily detected in hydrolysates of
red cell membrane lipid extracts. Levels of CME in erythrocyte
membrane lipids from control subjects and diabetic patients
are compared in Fig. 5. CME values were, respectively, 0.135 6
0.054 and 0.146 6 0.081 mmol/mol of ethanolamine; these data
were calculated excluding the two high CME values shown in
parentheses because they were .2 S.D. above the mean. The
mean CME values were not significantly different using nonparametric, Mann-Whitney analysis. For comparison, results
of analyses of CML and the Amadori compound, FL, on membrane protein fractions from these same samples are also
shown in Fig. 5. CML concentrations in control and diabetic
samples were 0.213 6 0.063 and 0.184 6 0.062 mmol/mol of
lysine, respectively, and were also not significantly different.
Of note, the ratio of CME/ethanolamine in the lipid fraction
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SCHEME 1. Possible routes to formation of CME in glycoxidation and/or lipoxidation reactions.
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TABLE I
Recovery of CME in PE incubated under oxidative and
antioxidative conditions
PE samples were incubated for 2 weeks in 0.2 M phosphate buffer, pH
7.4, at 37 °C, and the concentrations of CME and ethanolamine were
determined as described under “Experimental Procedures.”
Phospholipid

DO-PE (14 mM)
DO-PE (14 mM) 1 glucose (500 mM)
LP-PE (1.4 mM)

Oxidative

Antioxidative

mmol of CME/mol of
ethanolamine
0
17.7
2.7
8.7
0

was similar to the ratio of CML/lysine in the protein fraction,
suggesting an overall similar extent of carboxymethylation of
aminophospholipids and proteins in red cell membranes. At the
same time, FL values, reflecting both ambient glucose concentration and steady state level of protein glycation (1), were
elevated in a statistically significant fashion in diabetic (5.27 6
1.42 mmol/mol of lysine) versus control samples (2.13 6 1.33
mmol/mol of lysine, p , 0.01). The approximately 2.5-fold increase in mean FL concentration is comparable to the approximate 2-fold increase in mean HbA1c values, and there was an
overall significant correlation between FL and HbA1c values
(r 5 0.54, p 5 0.005).
Measurement of CME and CML in Human Urine—As shown
in Fig. 6, the mean concentrations of CM species in normal
urine were 1.82 6 0.70 nmol of CME/mg of creatinine and
5.58 6 2.11 nmol of CML/mg of creatinine, respectively, corresponding to a CML/CME ratio of 2.6. CME is present in urine
primarily in its free form, i.e. as the product of hydrolysis of
CM-PE (data not shown), suggesting active catabolism of the
latter compound. CME and CML concentrations in the urine of

FIG. 4. Detection of CME in a human red cell membrane lipid
extract. Selected ion chromatograms are shown for characteristic CME
ions in a lipid extract from control subject (A) and internal standard
d4-CME (B).

diabetic patients were 2.92 6 1.76 nmol of CME/mg of creatinine and 8.53 6 4.96 nmol of CML/mg of creatinine, respectively. Although the means were somewhat higher than for the
control population, they did not reach statistical significance.
In a previous study, using a larger number of samples, we
reported a modest, though significant elevation of urinary CML
in diabetes (19). In the present study there was, however, a
strong correlation between urinary CME and CML (r 5 0.737,
p 5 0.0003, n 5 9).
Immunochemical Detection of CME by Anti-AGE Protein Antibody—We have previously shown that CML-BSA is a potent
competitor for the recognition of AGE-RbSA by antiserum
PSR-1, demonstrating that CML is a dominant AGE antigen
(18). CML as the free amino acid is a significantly weaker
competitor, about 103–104 times less efficient than CML-BSA.
As shown in Fig. 7, CME was comparable to CML in inhibiting
the recognition of AGE-RbSA by the PSR-1 antiserum. Ethanolamine, like lysine (not shown), was completely ineffective.
DISCUSSION

In this study we describe the detection and measurement of
a CM lipid, CME, in human membrane lipids and urine. Based
on the concentration of CME in ghost membranes, ;0.14 mmol/
mol of PE (Fig. 5), and the concentration of PE in red cell
membranes, ;1 mg/ml of packed red cells (23) (average molecular mass for PE, 800 Da), there is an estimated 0.18 nmol of
CME/ml of packed erythrocytes. From the recovery of ;2 nmol
of CME/mg of creatinine (Fig. 6) and a mean daily excretion of
1.4 g of creatinine for a 70-kg subject, about 2.8 mmol (0.3 mg of
CME) are excreted daily by a healthy human adult. Since the
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FIG. 3. Formation of CME during lipoxidation and glycoxidation of PE. Traces shown are SIM chromatograms of hydrolysates from
phospholipid incubations carried out at 37 °C for 2 weeks under aerobic
conditions. A, LP-PE (1.4 mM) incubated in 0.5 M phosphate buffer, pH
7.4; B, DO-PE (14 mM) incubated in buffer with 500 mM glucose. No
CME was present in either original phospholipid preparation. Retention times and mass spectra of ethanolamine and CME were the same
as those obtained for TFAME derivatives of authentic CME and ethanolamine shown in Fig. 2.
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FIG. 6. Levels of CME and CML in human urine. Fasting urine
was collected from the same subjects shown in Fig. 5. CME and CML
were analyzed as described under “Experimental Procedures.” C,
control; D, diabetic subject. n 5 11 for all analyses except n 5 9 for
control CME.

average 70-kg subject has about 2 liters of packed red cells and
;1% of red cells turnover/day (average red cell life span, 120
days), only about 4 nmol of the daily urinary excretion of CME
can be attributed to red cell membrane degradation. This estimate emphasizes that .99% of the 2.8 mmol of CME recovered
daily in urine arises from the normal turnover of membrane
phospholipids in cells other than red cells. Thus, CME represents a natural metabolite formed during glycoxidative and/or
lipoxidative modification of phospholipids, and changes in
these levels in urine may reflect changes in overall oxidative
stress in vivo. CM-serine has also been detected in hydrolysates
of ghost lipids and in urine (data not shown), indicating that
carboxymethylation of both PE and phosphatidylserine occurs
under physiological conditions.
Origins of CME—Our model reactions show that CME can be
formed from either glucose or PUFA under oxidizing conditions. It is difficult to make a direct comparison of the relative
efficiency of each substrate in forming CME. Thus, in in vitro

FIG. 7. Immunochemical detection of CME by anti-AGE protein antibody. Competitive ELISA assays were performed after coating wells with AGE-RbSA and the addition of anti-AGE-protein antibody, PSR-1, with indicated amounts of competing antigens. EA,
ethanolamine. Data are expressed as the ratio of absorbance of sample
(B) to absorbance in sample incubated in the absence of competitor (B0)
after background subtraction.

experiments (Table I), glucose, which is resistant to autoxidation compared with PUFA, was present at a 33-fold molar
excess over free amino groups, whereas the PUFA (linoleic
acid) in LP-PE is present at the same concentration as the
amino group. Since aminophospholipids form micelles in aqueous buffers, it is likely that reactive intermediates formed
during peroxidation of PUFA in situ may be present at very
high local concentrations. At this point we can only speculate
about the metabolic origin of CM-PE. It is difficult to anticipate
which of the routes, glycoxidation, glucose, or PUFA autoxidation, shown in Scheme 1 predominates in vivo, and thus CME,
like CML, may be both a glycoxidation and lipoxidation prod-
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FIG. 5. Comparison of CME, CML, and FL in human red blood cell membrane lipids and proteins. CME, CML, and FL were analyzed
as described under “Experimental Procedures.” C, control subjects; D, diabetic patients. n 5 11 for FL and CME analyses; n 5 9 and 8 for CML
in control and diabetic subjects, respectively.
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(18), emphasizing that CM phospholipids in lipoproteins may
contribute to the AGE content of serum measured by ELISA.
Although we do not know how much better the recognition of
CM-PE in membrane or other lipoproteins may be, by analogy
to the results obtained for free CML and CML-BSA, CM-PE
may be an important epitope recognized by anti-AGE protein
antisera. Indeed, some of the AGE lipids described in low
density lipoprotein by Bucala et al. (15, 16) may be CM-aminophospholipids. Although the antibody used in their analyses
was reported to be unreactive toward CML (17), present knowledge suggests that, given the significantly lower reactivity of
free CML compared with protein-bound CML to anti-AGE protein antibody (18, Fig. 6), the amount of competing free CML
used in their experiments may not have been sufficient to yield
effective competition. At the same time, it should be noted that
these workers reported a 4-fold increase of AGE lipids in low
density lipoprotein from diabetic patients versus healthy subjects (15, 16), suggesting a greater increase in Maillard modification of aminophospholipids in diabetes than indicated by
our results. The differences between our results may reflect
differences in the severity of complications in the patient
groups. Finally, Kume et al. (30), using a monoclonal antibody
to AGE-protein, 6D12, reported the presence of AGEs in frozen
sections prepared from atherosclerotic tissue of normoglycemic
humans. This antibody has since been shown to recognize CML
(31); however, it is possible that both CM protein and lipid may
have been detected in this study.
In summary, we describe the detection of CM-PE in vivo and
present quantitative data on its concentration in human red
blood cell membrane lipids and on the concentration of its
metabolite, CME, in urine. We also demonstrate that CME
may be formed by autoxidation of both carbohydrate and lipid.
Measurements of CME in different tissues should prove useful
for assessing the role of glycoxidation and lipoxidation or, more
generally, carbonyl stress (32) in the pathogenesis of diabetes,
its complications, and other disease processes.
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uct. Jain et al. (24, 25) previously reported a serine-malondialdehyde-ethanolamine cross-link in red cell membranes, which
is another nonenzymatically modified aminophospholipid
found in vivo, but in this case the origin of the modification
from lipid peroxidation is more certain. This cross-link structure was reported to be elevated approximately 3-fold in diabetic subjects (24), but the complication status of the subjects
was not described.
Physiological Significance of CME—CME is quantitatively a
minor fraction of total ethanolamine, representing about only
0.01% modification of red blood cell membrane phospholipid. It
can be estimated that there are ;104 molecules of CME/red
cell. Thus, there are ;1010 red cells and 0.18 nmol of CME (see
above) or ;1014 molecules of CME/ml of packed red cells,
yielding a value of ;104 molecules of CME/red cell. Anticipating that serine will be modified to a similar extent, it seems
likely that CM lipids, like CML, are biomarkers rather than
important effectors of damage in tissue. At the same time,
AGEs are hypothesized to play a key role as causative agents in
the pathogenesis of diabetic complications, and in agreement
with this notion, CML and other AGEs are elevated in lens and
skin collagen of diabetic patients and correlate with severity of
complications (8 –10, 26). Since the patients participating in
this study were free of complications, it is not surprising that
there were not differences in markers of oxidative damage
between control and patient populations. Studies are in progress to examine levels of CM lipids in diabetic patients with
more extensive vascular complications who are predicted to
show differences in the levels of both carboxymethylated lipids
and protein. Finally, consistent with the red cell data, neither
CME or CML concentrations were significantly elevated in the
urine of the diabetic subjects in this study. The modest but
statistically insignificant increase in urinary CM species is
more than sufficiently explained by the larger increases in the
amounts of oxidizable substrates (glucose, glycated proteins
and glycated aminophospholipids, and triglycerides) without
the necessity of invoking a diabetes-dependent increase in oxidative stress.
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inner layer of the red cell membrane bilayer, they become
externalized under a variety of pathological conditions, including oxidative stress to red cells (27, 28). Should this also be the
case for CM lipids (and/or CML); once exposed on the outer
membrane of erythrocytes, they may have a role in the recognition by and binding to receptors for AGEs reported on a
variety of cell types, including endothelial cells and macrophages. Wautier et al. (29) describe the interaction of erythrocytes from diabetic rats with one such receptor termed RAGE.
According to these authors, this interaction could contribute to
the shortened half-life of red blood cells isolated from diabetic
rats when injected into normal rats and also lead to a localized
increase in oxidative stress in the vascular wall, ultimately
contributing to the pathogenesis of diabetic vascular disease.
The AGE structure(s) on the surfaces of red cells that mediate
their interaction with the RAGE has not been characterized. It
seems possible that CM lipids (and CML) measured in the
present study could form part of an array of negative charge
that may be recognized by RAGE or other scavenger receptors
involved in erythrocyte turnover.
CME as an AGE Antigen—Because the terminal
–CH2CH2NHCH2COOH moieties of CM-lysine and the predicted structure of CM-PE (Fig. 1) are identical, it seemed
likely that anti-AGE protein antibodies might also recognize
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Carboxymethylation of Phospholipids
22. Wells-Knecht, K. J., Zyzak, D. V., Litchfield, J. E., Thorpe, S. R., and Baynes,
J. W. (1995) Biochemistry. 34, 3702–3709
23. Beutler, E., Lichtman, M. A., Coller, B. S., and Kipps, T. J., (eds) (1995)
Williams Hematology, 5th Ed., pp. 364 –365, McGraw-Hill Inc., New York
24. Jain, S. K. (1988) Biochim. Biophys. Acta 937, 205–210
25. Jain, S. K., McVie, R., Duett, J., and Herbst, J. J. (1989) Diabetes 38,
1539 –1543
26. Lyons, T. J., Silvestri, G., Dunn, J. A., Dyer, D. G., and Baynes, J. W. (1991)
Diabetes 40, 1010 –1015
27. Jain, S. K. (1985) J. Clin. Invest. 76, 281–286

17479

28. Schroit, A. J., Madsen, J. W., and Tanaka, Y. (1985) J. Biol. Chem. 260,
5131–5136
29. Wautier, J. L., Wautier, M. P., Schmidt, A. M., Anderson, G. M., Hori, O.,
Zoukourian, C., Capron, L., Chappey, O., Yan, S. D., Brett, J., Guillausseau,
P. J., and Stern, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7742–7746
30. Kume, S., Takeya, M., Mori, T., Araki, N., Suzuki, H., Horiuchi, S., Kodama,
T., Miyauchi, Y., and Takahashi, K. (1995) Am. J. Pathol. 147, 654 – 667
31. Ikeda, K., Higashi, T., Sano, H., Jinnouchi, Y., Yoshida, M., Araki, T., Ueda, S.,
and Horiuchi, S. (1996) Biochemistry 35, 8075– 8083
32. Lyons, T. J., and Jenkins, A. J. (1997) Diabetes Rev., in press

Downloaded from http://www.jbc.org/ at USC SCHOOL OF MEDICINE on September 30, 2014

